| Global Data Intelligence Center |
| 구분 |
보고서 (영문) |
업로드 날짜 |
| 제약/바이오/임상시험 |
PDS Biotech to Pursue Pivotal Trial in HNSCC After Exciting Phase II Results |
11-17-2023 |
| Novo Nordisk Launches Combo Trial of Pipeline Drug CagriSema versus Eli Lilly’s Newly Approved Zepbound |
11-17-2023 |
| Post Hoc Analysis of SCORED Trial Sheds Positive Light on Inpefa for Heart Failure |
11-17-2023 |
| Positive Phase III Data Could Help Position Ubrelvy in a Crowded Migraine Market |
11-20-2023 |
| AstraZeneca’s Imfinzi Phase III Trial Raises Trial Design Questions |
11-21-2023 |
| Truqap’s First Approval Is Not What AstraZeneca Was Hoping for |
11-22-2023 |
| Roche Attempts to Expand in the Lupus Nephritis Treatment Landscape with an Oncology Drug After Promising Phase II Trials |
11-22-2023 |
| VPAS Is Dead, Long Live VPAG—Could the UK’s New Clawback Revision Save the Day |
11-27-2023 |
| Where do Anti-Tumor Necrosis Factor Like Cytokine Agents go After Their Initial Excitement? |
11-30-2023 |
| BioPharmaceutical Outsourcing Report |
11-30-2023 |
| Madrigal Ramps Up Preparations for Commercial Launch of Resmetirom in NASH |
11-30-2023 |
| Waning Focus on Stimulant Abuse Potential Could Negatively Affect Pipeline Non-stimulants |
11-30-2023 |
| Partnership Deals for Psychedelic Drugs Take a Trip with 500% Surge in 2023 |
12-01-2023 |
| 질환별 |
Experts Believe Gene Therapy Offers Potential to Impact Gaucher Disease Market |
11-21-2023 |
| World AIDS Day 2023 Highlights Community Leadership to End the HIV Epidemic |
12-01-2023 |
| 컨퍼런스/심포지엄/학회 |
CPHI Barcelona: A Tough Funding Environment Necessitates Integration and Flexibility for ATMP Manufacturing |
11-24-2023 |
| The Movement Towards Trial Transparency |
11-29-2023 |
